OSI Pharmaceuticals Inc. on Thursday announced a new approval for its cancer drug Tarceva, saying it was approved in Europe as a maintenance treatment for advanced non-small cell lung cancer.
European Union regulators cleared Tarceva for use in patients whose disease is unchanged after four cycles of chemotherapy, OSI said. OSI developed Tarceva, and the drug is marketed through a partnership with Swiss drugaker Roche. The FDA approved Tarceva as a lung cancer maintenance therapy on April 16.
Maintenance drugs are used to prevent the spread of cancer that stopped growing after an earlier therapy.
Tarceva is also used to treat pancreatic cancer and lung cancer patients that has advanced after a chemotherapy regimen.
OSI shares rose 52 cents to $58.77 in morning trading.